Biomedical subjects
Henry W Buck
Publications and source records attributed to Henry W Buck.
Metoclopramide pretreatment attenuates emergency contraceptive-associated nausea.
OBJECTIVE: The study was undertaken to determine whether metoclopramide pretreatment attenuates side effects associated with high-dose estrogen/progestin emergency contraception in at-risk patients. STUDY DESIGN: This was a randomized, prospective, double-blind, placebo-controlled study at the University of Kansas. Patients (141) requesting emergency contraception and lacking contraindications were offered entry in the study. Both the treatment (metoclopramide 10 mg) and placebo groups received active emergency contraception. Participants evaluated symptom severity with a 12-question survey tool developed for this study. RESULTS: Metoclopramide pretreatment provided protection against nausea and cramping associated with estrogen/progestin emergency contraception. The average scores on a 10-point scale for the treatment group and placebo group were as follows: nausea 3.2 versus 4.8 (P =.01) and cramping 0.9 versus 2.2 (P <.01), indicating less severe nausea and cramping in the treatment group. CONCLUSION: Metoclopramide pretreatment attenuates the nausea and cramping associated with Yuzpe emergency contraceptive treatment.
Treatment of vaginal intraepithelial neoplasia (primarily low grade) with imiquimod 5% cream.
OBJECTIVE: Treatment of human papillomavirus (HPV)-associated vaginal lesions (vaginal intraepithelial neoplasia [VAIN]) can be expensive, tedious, and morbidity inducing. Imiquimod 5% cream, a safe and effective treatment of external genital warts, enhances the immune response to HPV infection. MATERIALS AND METHODS: Imiquimod 5% cream was used to treat 56 young women with VAIN. One sachet of cream (0.25 g) was placed in the vagina with an applicator once weekly for 3 weeks (except for the first four patients, who were treated twice weekly). RESULTS: Thirty-six of the 42 patients (86%) available for follow-up were clear of VAIN lesions (as assessed by colposcopy) 1 week or later after the last dose of treatment. The remaining six patients cleared after a total of two (five patients) and three (one patient) treatment cycles. Vulvar or vestibular excoriation was reported in only 2 of 56 patients. No patients had vaginal ulceration. CONCLUSIONS: A very low dosing regimen of imiquimod 5% cream appears to be an effective and well-tolerated treatment for VAIN (primarily low grade.).
ASCCP Patient Management Guidelines: Pap Test Specimen Adequacy and Quality Indicators.
OBJECTIVES: To provide management guidelines according to Pap test specimen adequacy based on literature review and expert opinion. METHODS: A task force named by the American Society for Colposcopy and Cervical Pathology conducted a literature review and discussed appropriate management. The steering committee of the American Society for Colposcopy and Cervical Pathology and other experts reviewed the guidelines. RESULTS: The guidelines recommend a repeat Pap test in 12 months for most women who are undergoing routine annual/biennial screening if the current Pap test is negative but either lacks an endocervical/transformation zone component or is partially obscured. Indications for considering an earlier repeat are also provided. The preferred management for unsatisfactory Pap tests is a repeat Pap test within a short interval of 2 to 4 months. CONCLUSIONS: The management guidelines will help promote optimal and uniform follow-up of women's Pap tests, according to Pap test specimen adequacy.
ASCCP patient management guidelines: Pap test specimen adequacy and quality indicators.
Our objective was to provide management guidelines according to Papanicolaou (Pap) test specimen adequacy based on literature review and expert opinion. A task force named by the American Society for Colposcopy and Cervical Pathology (ASCCP) conducted a literature review and discussed appropriate management. The Steering Committee of the ASCCP and other experts reviewed the guidelines. The guidelines recommend a repeated Pap test in 12 months for most women undergoing routine annual/biennial screening if the current Pap test is negative but either lacks an endocervical/ transformation zone component or is partially obscured. Indications for considering an earlier repeat are also provided. The preferred managementfor unsatisfactory Pap tests is a repeated Pap test within a short interval of 2 to 4 months. The management guidelines will help promote optimal and uniform follow-up of women according to Pap test specimen adequacy.